ArticleBMC medical informatics and decision making2024
Fusion-driven semi-supervised learning-based lung nodules classification with dual-discriminator and dual-generator generative adversarial network.
Article in BMC medical informatics and decision making, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Hybrid approach with convolutional neural network and regression models for age estimation in panoramic radiographs.International journal of legal medicine · 2026Observational
- MedScanGAN: Synthetic PET & CT Scan Generation Using Conditional Generative Adversarial Networks for Medical AI Data Augmentation.Bioengineering (Basel, Switzerland) · 2026Article
- Feature stabilization in convolutional neural networks using Proportional Integral Controller for lung nodule classification.Frontiers in artificial intelligence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe detection and classification of lung nodules are crucial in medical imaging, as they significantly impact patient outcomes related to lung cancer diagnosis and treatment. However, existing models often suffer from mode collapse and poor generalizability, as they fail to capture the complete diversity of the data distribution. This study addresses these challenges by proposing a novel generative adversarial network (GAN) architecture tailored for semi-supervised lung nodule classification.
methodsThe proposed DDDG-GAN model consists of dual generators and discriminators. Each generator specializes in benign or malignant nodules, generating diverse, high-fidelity synthetic images for each class. This dual-generator setup prevents mode collapse. The dual-discriminator framework enhances the model's generalization capability, ensuring better performance on unseen data. Feature fusion techniques are incorporated to refine the model's discriminatory power between benign and malignant nodules. The model is evaluated in two scenarios: (1) training and testing on the LIDC-IDRI dataset and (2) training on LIDC-IDRI, testing on the unseen LUNA16 dataset and the unseen LUNGx dataset.
resultsIn Scenario 1, the DDDG-GAN achieved an accuracy of 92.56%, a precision of 90.12%, a recall of 95.87%, and an F1 score of 92.77%. In Scenario 2, the model demonstrated robust performance with an accuracy of 72.6%, a precision of 72.3%, a recall of 73.82%, and an F1 score of 73.39% when testing using Luna16 and an accuracy of 71.23%, a precision of 67.56%, a recall of 73.52%, and an F1 score of 70.42% when testing using LungX. The results indicate that the proposed model outperforms state-of-the-art semi-supervised learning approaches.
conclusionsThe DDDG-GAN model mitigates mode collapse and improves generalizability in lung nodule classification. It demonstrates superior performance on both the LIDC-IDRI and the unseen LUNA16 and LungX datasets, offering significant potential for improving diagnostic accuracy in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.